KRW 14020.0
(-1.2%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 146.04 Billion KRW | 25.39% |
2022 | 116.47 Billion KRW | -6.04% |
2021 | 123.96 Billion KRW | 136.23% |
2020 | 52.47 Billion KRW | 2.57% |
2019 | 51.16 Billion KRW | 82.73% |
2018 | 28 Billion KRW | 180.0% |
2017 | 10 Billion KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | -100.0% |
2014 | 3 Billion KRW | 0.0% |
2013 | 3 Billion KRW | 0.0% |
2012 | 3 Billion KRW | -51.61% |
2011 | 6.2 Billion KRW | 3.33% |
2010 | 6 Billion KRW | -49.03% |
2009 | 11.77 Billion KRW | 142.0% |
2008 | 4.86 Billion KRW | -3.81% |
2007 | 5.05 Billion KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 163.92 Billion KRW | 12.24% |
2024 Q2 | 191.3 Billion KRW | 16.7% |
2023 Q2 | 114.2 Billion KRW | 0.14% |
2023 Q4 | 146.04 Billion KRW | 19.5% |
2023 FY | 146.04 Billion KRW | 25.39% |
2023 Q1 | 114.03 Billion KRW | -2.09% |
2023 Q3 | 122.22 Billion KRW | 7.02% |
2022 Q1 | 122.71 Billion KRW | -1.01% |
2022 FY | 116.47 Billion KRW | -6.04% |
2022 Q4 | 116.47 Billion KRW | -3.41% |
2022 Q3 | 120.59 Billion KRW | -1.32% |
2022 Q2 | 122.2 Billion KRW | -0.42% |
2021 FY | 123.96 Billion KRW | 136.23% |
2021 Q2 | 94.19 Billion KRW | 39.38% |
2021 Q1 | 67.58 Billion KRW | 28.78% |
2021 Q3 | 122.64 Billion KRW | 30.2% |
2021 Q4 | 123.96 Billion KRW | 1.08% |
2020 FY | 52.47 Billion KRW | 2.57% |
2020 Q4 | 52.47 Billion KRW | -0.34% |
2020 Q2 | 51.16 Billion KRW | 0.38% |
2020 Q3 | 52.65 Billion KRW | 2.91% |
2020 Q1 | 50.96 Billion KRW | -0.38% |
2019 Q3 | 48.26 Billion KRW | 1.5% |
2019 Q2 | 47.55 Billion KRW | 26.1% |
2019 FY | 51.16 Billion KRW | 82.73% |
2019 Q4 | 51.16 Billion KRW | 6.0% |
2019 Q1 | 37.71 Billion KRW | 34.68% |
2018 Q4 | 28 Billion KRW | 47.37% |
2018 FY | 28 Billion KRW | 180.0% |
2018 Q1 | 10 Billion KRW | 0.0% |
2018 Q2 | 16 Billion KRW | 60.0% |
2018 Q3 | 19 Billion KRW | 18.75% |
2017 Q1 | - KRW | 0.0% |
2017 Q4 | 10 Billion KRW | 0.0% |
2017 FY | 10 Billion KRW | 0.0% |
2017 Q2 | 10 Billion KRW | 0.0% |
2017 Q3 | 10 Billion KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2015 FY | - KRW | -100.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q4 | - KRW | 0.0% |
2015 Q2 | - KRW | -100.0% |
2015 Q1 | 3 Billion KRW | 0.0% |
2014 Q1 | 3 Billion KRW | 0.0% |
2014 FY | 3 Billion KRW | 0.0% |
2014 Q4 | 3 Billion KRW | 0.0% |
2014 Q3 | 3 Billion KRW | 0.0% |
2014 Q2 | 3 Billion KRW | 0.0% |
2013 Q3 | 3 Billion KRW | 0.0% |
2013 Q2 | 3 Billion KRW | 0.0% |
2013 Q4 | 3 Billion KRW | 0.0% |
2013 FY | 3 Billion KRW | 0.0% |
2013 Q1 | 3 Billion KRW | 0.0% |
2012 Q1 | 6 Billion KRW | 0.0% |
2012 FY | 3 Billion KRW | -51.61% |
2012 Q4 | 3 Billion KRW | 0.0% |
2011 FY | 6.2 Billion KRW | 3.33% |
2011 Q2 | 6 Billion KRW | 0.0% |
2011 Q1 | 6 Billion KRW | 0.0% |
2011 Q3 | 6 Billion KRW | 0.0% |
2010 Q3 | 6 Billion KRW | 0.0% |
2010 Q1 | 11.77 Billion KRW | 0.0% |
2010 FY | 6 Billion KRW | -49.03% |
2010 Q4 | 6 Billion KRW | 0.0% |
2010 Q2 | 6 Billion KRW | -49.03% |
2009 Q3 | 6.25 Billion KRW | -13.79% |
2009 FY | 11.77 Billion KRW | 142.0% |
2009 Q4 | 11.77 Billion KRW | 88.34% |
2009 Q1 | 7.2 Billion KRW | 48.02% |
2009 Q2 | 7.25 Billion KRW | 0.7% |
2008 Q3 | 6.52 Billion KRW | -13.52% |
2008 Q1 | 5.13 Billion KRW | 1.53% |
2008 FY | 4.86 Billion KRW | -3.81% |
2008 Q2 | 7.54 Billion KRW | 47.05% |
2008 Q4 | 4.86 Billion KRW | -25.5% |
2007 Q1 | - KRW | 0.0% |
2007 Q4 | 5.05 Billion KRW | 1.45% |
2007 FY | 5.05 Billion KRW | 0.0% |
2007 Q2 | - KRW | 0.0% |
2007 Q3 | 4.98 Billion KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -202.66% |
Yuhan Corporation | 230.07 Billion KRW | 36.52% |
Yuhan Corporation | 230.07 Billion KRW | 36.52% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -270.617% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -270.617% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | -270.617% |
Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 61.773% |
Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 16.96% |
Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 78.891% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 14.23% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 14.23% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 14.23% |
SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -24426.145% |
Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 68.795% |
Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -237.509% |
HANDOK Inc. | 300.01 Billion KRW | 51.319% |
Jeil Pharma Holdings Inc | 173.03 Billion KRW | 15.593% |
Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -376.32% |
Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -83.972% |
Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 19.308% |
Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -61232.949% |
Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -118.369% |
Boryung Corporation | 204.21 Billion KRW | 28.483% |
Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -272.529% |
Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -23.105% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -71.501% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -71.501% |
Suheung Co., Ltd. | 467.85 Billion KRW | 68.783% |
Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 38.02% |
Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -11217.035% |
Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -23008.196% |
MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -61.413% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -216.458% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -216.458% |
Korea United Pharm Inc. | 40.33 Billion KRW | -262.056% |
CKD Bio Corp. | 146.92 Billion KRW | 0.597% |
Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 68.905% |
JW Holdings Corporation | 554.58 Billion KRW | 73.665% |
REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 35.105% |
Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 74.505% |
Dong-A ST Co., Ltd. | 406.7 Billion KRW | 64.09% |
Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 33.542% |
JW Lifescience Corporation | 46.31 Billion KRW | -215.355% |
Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 32.956% |
Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -71.893% |
Hana Pharm Co., Ltd. | 26.53 Billion KRW | -450.444% |